Integra LifeSciences | IART - Cash And Equivalent


Integra LifeSciences reported $236.81M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Abbott USD 6.8B 1.72B Mar/2026
AtriCure USD 146.16M 21.26M Mar/2026
Baxter International USD 2.02B 51M Mar/2026
Becton, Dickinson and Co. USD 813M 73M Mar/2026
Boston Scientific USD 1.45B 512M Mar/2026
CONMED USD 40.82M 1.89M Dec/2025
Cooper Companies USD 124.9M 14.3M Dec/2025
Dexcom USD 1.12B 200.5M Mar/2026
Edwards Lifesciences USD 2.4B 538M Mar/2026
Globus Medical USD 560.95M 34.79M Mar/2026
HeartBeam USD 2.04M 2.34M Mar/2026
Insulet USD 480.4M 235.7M Mar/2026
Integra LifeSciences USD 236.81M 1.76M Mar/2026
Intuitive Surgical USD 8.63B 646.3M Jun/2026
J&J USD 21.69B 1.98B Mar/2026
Medtronic USD 1.15B 135M Dec/2025
Merit Medical Systems USD 488.08M 41.68M Mar/2026
Orthofix International USD 120.28M 38.25M Mar/2026
Stryker USD 2.88B 1.13B Mar/2026
Tandem Diabetes Care USD 179.32M 88.69M Mar/2026
Teleflex USD 309.41M 69.15M Mar/2026
Zimmer Biomet Holdings USD 424.2M 167.7M Mar/2026